O
Ole Lederballe-Pedersen
Researcher at Aarhus University
Publications - 27
Citations - 10503
Ole Lederballe-Pedersen is an academic researcher from Aarhus University. The author has contributed to research in topics: Left ventricular hypertrophy & Losartan. The author has an hindex of 21, co-authored 27 publications receiving 10289 citations.
Papers
More filters
Journal ArticleDOI
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristiansson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel +14 more
TL;DR: Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated, while new-onset diabetes was less frequent with losartan.
Journal ArticleDOI
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lars H Lindholm,Hans Ibsen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristiansson,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Peter Aurup,Jonathan M. Edelman,Steven M. Snapinn +17 more
TL;DR: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH.
Journal ArticleDOI
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study
Hans Ibsen,Michael H. Olsen,Kristian Wachtell,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Ulf de Faire,F Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Ying Wan +16 more
TL;DR: Monitoring of albuminuria should be an integrated part of the management of hypertension if it is not decreased by the patient’s current antihypertensive and other treatment, and further intervention directed toward blood pressure control and other modifiable risks should be considered.
Journal ArticleDOI
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
Kristian Wachtell,Hans Ibsen,Michael H. Olsen,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Gareth Beevers,Ulf de Faire,Frej Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Krister Kristianson,Ole Lederballe-Pedersen,Markku S. Nieminen,Peter M. Okin,Per Omvik,Suzanne Oparil,Hans Wedel,Steven M. Snapinn,Peter Aurup +21 more
TL;DR: This large prospective study of hypertensive patients with left ventricular hypertrophy found that increasing albuminuria is associated with a graded increase in risk, and any threshold identified would be much lower than the threshold traditionally defined in diabetic populations.
Journal ArticleDOI
The impact of serum uric acid on cardiovascular outcomes in the LIFE study
Aud Høieggen,Michael H. Alderman,Sverre E. Kjeldsen,Stevo Julius,Richard B. Devereux,U de Faire,Frej Fyhrquist,Hans Ibsen,Krister Kristianson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Hans Wedel,Cong Chen,Björn Dahlöf +16 more
TL;DR: The increase in SUA over 4.8years in the LIFE study was attenuated by losartan compared with atenolol treatment, appearing to explain 29% of the treatment effect on the primary composite end point.